Inventor
BARAS ARIS
US39 patents
⚠️ This page may combine multiple inventors who share the name “BARAS ARIS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
38 patentsUS10961583B2Mar 30, 2021
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA9 citations82
US10787647B2Sep 29, 2020
HSD17B13 variants and uses thereof
REGENERON PHARMA10 citations81
US11845963B2Dec 19, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11753628B2Sep 12, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11702700B2Jul 18, 2023
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA4 citations71
US11180757B1Nov 23, 2021
17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA3 citations71
US11957704B2Apr 16, 2024
Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors
REGENERON PHARMA2 citations70
US11939635B2Mar 26, 2024
Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)
REGENERON PHARMA2 citations70
US11759476B2Sep 19, 2023
Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors
REGENERON PHARMA2 citations70
US11485958B2Nov 1, 2022
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations70
US11584966B2Feb 21, 2023
Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof
REGENERON PHARMA2 citations69
US12359201B2Jul 15, 2025
17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA0 citations61
US11865134B2Jan 9, 2024
Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
REGENERON PHARMA0 citations60
US12577562B2Mar 17, 2026
Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors
REGENERON PHARMA0 citations59
US12286677B2Apr 29, 2025
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA0 citations59
US12258627B2Mar 25, 2025
Kelch domain containing 7B (KLHDC7B) variants and uses thereof
REGENERON PHARMA0 citations59
US12163192B2Dec 10, 2024
Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof
REGENERON PHARMA0 citations59
US11820982B2Nov 21, 2023
Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors
REGENERON PHARMA1 citations59
US11674177B2Jun 13, 2023
Kelch domain containing 7B (KLHDC7B) variants and uses thereof
REGENERON PHARMA1 citations59
US11512309B2Nov 29, 2022
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
REGENERON PHARMA0 citations59
US11752197B2Sep 12, 2023
Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
REGENERON PHARMA0 citations58
US12472241B2Nov 18, 2025
Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors
REGENERON PHARMA0 citations57
US12123001B2Oct 22, 2024
Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors
REGENERON PHARMA0 citations57
US11767526B2Sep 26, 2023
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
REGENERON PHARMA0 citations57
US11708415B2Jul 25, 2023
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
REGENERON PHARMA1 citations57
US12264366B2Apr 1, 2025
Genome-based methods for reducing cardiovascular risk
REGENERON PHARMA0 citations56
US11845989B2Dec 19, 2023
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
REGENERON PHARMA0 citations56
US12234460B2Feb 25, 2025
Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
REGENERON PHARMA0 citations54
US12018259B2Jun 25, 2024
Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
REGENERON PHARMA0 citations54
US11891607B2Feb 6, 2024
Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
REGENERON PHARMA0 citations54
US11773393B2Oct 3, 2023
Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
REGENERON PHARMA0 citations54
US12370257B2Jul 29, 2025
Materials and methods of treating MHC-I-opathy risk haplotypes
REGENERON PHARMA0 citations52
US12186378B2Jan 7, 2025
Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists
REGENERON PHARMA0 citations47
US12378557B2Aug 5, 2025
Treatment of sepsis with PCSK9 and LDLR modulators
REGENERON PHARMA0 citations46
US12070460B2Aug 27, 2024
Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors
REGENERON PHARMA0 citations45
US12215322B2Feb 4, 2025
Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors
REGENERON PHARMA0 citations41
US12157891B2Dec 3, 2024
Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
REGENERON PHARMA0 citations38
US12584174B2Mar 24, 2026
Treatment of psoriasis with interferon induced Helicase C domain 1 (IFIH1) inhibitors
REGENERON PHARMA0 citations37